Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.11T
Market cap1.11T
Price-Earnings ratio
42.09
Price-Earnings ratio42.09
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.51M
Average volume2.51M
High today
$1,175.20
High today$1,175.20
Low today
$1,135.00
Low today$1,135.00
Open price
$1,143.00
Open price$1,143.00
Volume
1.31M
Volume1.31M
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,174.18. The company's market cap stands at 1.11T, with a P/E ratio of 42.09 and a dividend yield of 0.55%.

During the trading session on 2026-07-21, Eli Lilly(LLY) shares reached a daily high of $1,175.20 and a low of $1,135.00. At a current price of $1,174.18, the stock is +3.5% higher than the low and still -0.1% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 1.31M, versus its average volume of 2.51M.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

LLY News

Washington Post 25m
GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science - The Washington Post

...

GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science - The Washington Post
Barron's 5h
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. Fo...

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
TipRanks 6h
Lilly tells Bloomberg ads ‘truthful,’ will defend against Novo suit ‘vigorously’

A spokesperson for Eli Lilly (LLY) told Bloomberg that the company’s weight loss drug ads are “truthful” and “transparent,” adding that the company will defend...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More LLY News

TipRanks 6h
Eli Lilly Hit with Lawsuit by Rival Novo Nordisk Over Weight-Loss Drug Ads

Novo Nordisk (NVO) has filed a lawsuit against rival pharmaceutical company Eli Lilly (LLY), claiming that advertising campaigns for its weight-loss drugs are d...

Investor's Business Daily 6h
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move

The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo? 7/16/2026 FDA advisors will debate the merits of seven peptides next week. The disc...

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
Simply Wall St 6h
Eli Lilly Stock And 2 Obesity Drug Shares Worth A Closer Look

The legal clash between Novo Nordisk and Eli Lilly over GLP-1 drug advertising puts a spotlight on how powerful marketing claims can be in shaping demand for ob...

Eli Lilly Stock And 2 Obesity Drug Shares Worth A Closer Look
The Wall Street Journal 8h
Weight-Loss Wars Latest: Novo Nordisk Sues Eli Lilly

Ozempic maker Novo Nordisk has filed a lawsuit against Eli Lilly, arguing it uses deceptive advertising to mislead consumers. The complaint accuses Eli Lilly o...

Weight-Loss Wars Latest: Novo Nordisk Sues Eli Lilly
The Wall Street Journal 8h
Novo Nordisk Files Deceptive Advertising Lawsuit Against Rival Eli Lilly

Novo Nordisk says it sent its rival a cease-and-desist letter in April. Mads Claus Rasmussen / AFP / Getty Images Novo Nordisk NOVO.B -1.68 %decrease; down poi...

Novo Nordisk Files Deceptive Advertising Lawsuit Against Rival Eli Lilly
TipRanks 8h
Novo Nordisk suing Eli Lilly over weight-loss ads, Bloomberg reports

Novo Nordisk (NVO) said in U.S. federal court that it is suing Eli Lilly (LLY), claiming that its competitor’s advertising for its obesity shot Zepbound and dia...

CNBC 8h
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Key Points Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed t...

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.